• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Bon Natural Life Limited

    7/11/25 12:08:48 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BON alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the month of July 2025

     

    Commission File Number 001-40517

     

    BON NATURAL LIFE LIMITED

    (Translation of registrant’s name into English)

     

    Room 601, Block C, Gazelle Valley, No.69, Jinye Road

    High-Tech Zone, Xi’an, Shaanxi, China

    People’s Republic of China

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

     

    Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

     

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

     

    Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

     

     

     

     

     

     

    Nasdaq Compliance

     

    As previously reported on a Form 6-K filed with the U.S. Securities and Exchange Commission on May 5, 2025, Bon Natural Life Limited (the “Company”) received notification letters from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”), stating that the Company that it was not in compliance with several continued listing requirements and was subject to delisting. Specifically, the Staff cited (i) non-compliance with the minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”); and (ii) concerns under Nasdaq Listing Rule 5101, pursuant to which Nasdaq may use its discretionary authority to delist a company where public interest concerns exist. In this case, the Staff referenced the Company’s issuance of securities that resulted in significant dilution to existing stockholders in its March 2025 offering.

     

    The Company submitted a plan of compliance (the “Compliance Plan”) to Nasdaq on May 16, 2025 and appeared before the Nasdaq Hearings Panel (the “Panel”) on June 5, 2025 to present its case for continued listing. On July 2, 2025, the Panel notified the Company that it granted the Company’s request to continue its listing on Nasdaq, and further confirmed that the Company is now in compliance with the Minimum Bid Price Requirement.

     

    The Panel also informed the Company that it will be subject to a Discretionary Panel Monitor for a period of one year, during which Nasdaq will monitor the Company’s ongoing compliance with the continued listing requirements.

     

    As of July 11, 2025, on a pre-split basis, 101,250,968 Class A ordinary shares have been issued pursuant to the Company’s March 2025 offering. The maximum number of Class A ordinary shares that may be issued upon full exercise of warrants issued in connection with the March 2025 offering is 116,666,648, representing the potential issuance of an additional 8,333,332 Class A ordinary shares.

     

    The Company is actively exploring options and, where feasible, will initiate discussions with investors who participated in the March 2025 offering to assess the possibility of mutually agreeable amendments to the terms of the securities, with the aim of addressing the dilutive impact on all shareholders by not only mitigating future potential dilution but also by thoroughly evaluating and seeking to reduce or remedy the dilution that has already been experienced as a result of the offering. Additionally, the Company has started to implement a share repurchase program to enhance shareholder value and potentially offset some of the dilution.

     

    Pursuant to the Company’s Compliance Plan, it is committed to avoiding the use of overly complex or inherently dilutive financing instruments in all future capital raising activities. The Company will seek to structure future financings in a manner that is transparent, responsible, and aligned with the long-term interests of its existing equity holders.

     

    Beyond timely filing of all required forms, the Company commits to proactively communicating with the Nasdaq Staff regarding any planned financing that could be considered material or complex. The Company will seek to discuss potential issues and ensure full alignment with Nasdaq’s expectations before any such future securities are offered or issued. As part of its due diligence for future offerings, the Company will carefully consider comparable transactions in the Nasdaq market to ensure its proposed terms align with best practices for shareholder protection and market integrity.

     

    The Company is committed to strengthening the independence of its board of directors and will review and enhance its processes for the approval of related- party transactions and significant financing activities, ensuring rigorous scrutiny and a primary focus on the interests of public shareholders.

     

    The Company has commenced a comprehensive review and will implement a robust internal control framework for all future securities issuances and Nasdaq reporting obligations. This will include (i) developing and implementing a mandatory pre-issuance checklist and due diligence process, requiring sign-off by legal counsel and senior management; (ii) assigning clear responsibility for Nasdaq communications and filings to dedicated, trained personnel; (iii) providing regular, updated training to relevant employees and directors on Nasdaq compliance requirements; and (iv) engaging external legal and compliance advisors on an ongoing basis to provide counsel on complex transactions and evolving regulatory landscapes.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: July 11, 2025 Bon Natural Life Limited
         
      By: /s/ Yongwei Hu
        Yongwei Hu
        Chairman and Chief Executive Officer

     

     

    Get the next $BON alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BON Announces Reciept of Nasdaq Compliance Letter

    XI'AN, China, Aug. 5, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced reciept of compliance notification from the Nasdaq Stock Market LLC. As previously reported on a Form 6-K filed with the U.S. Securities and Exchange Commission on July 11, 2025, Bon Natural Life Limited ( "the Company") received notification from the Nasdaq Hearings Panel (the "Panel") that the Company had regained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"). The Panel also advised the Company that it will be subject to a one-year Discretionary Panel M

    8/5/25 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    BON Launches AI-Powered New Drug Research and Development

    XI'AN, China, July 30, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or "the Company"), a leading provider of bio-ingredient solutions for the natural health and personal care industries, today announced the official launch of its AI-driven drug research and development (R&D) business. Leveraging its extensive library of natural compounds - many derived from Traditional Chinese Medicine (TCM) - the Company will apply artificial intelligence algorithms to identify high potential lead compounds, marking a significant evolution in its pharmaceutical strategy. A lead compound is a molecule with specific biological activity and a chemical structure that serves as a foundation

    7/30/25 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    BON Announces $22 Million Distribution Agreement for Weight Loss Products with Beijing Huahai Keyuan Technology Co., Ltd

    XI'AN, China, July 21, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural health and personal care industries, today announced it has entered into a non-exclusive sales distribution agreement with Beijing Huahai Keyuan Technology Co. Ltd. ("Huahai Keyuan"). The term of the agreement is 36 months with a total contract value of US$22 million. Pursuant to the agreement, Huahai Keyuan will sell and distribute Bon's natural weight loss product line across China and Southeast Asia. What sets BON apart is not only the science behind its formulation but also its exceptional user compliance. By eli

    7/21/25 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    SEC Filings

    View All

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    8/4/25 9:20:22 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    7/21/25 9:00:10 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    7/11/25 12:08:48 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Leadership Updates

    Live Leadership Updates

    View All

    Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

    XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

    4/25/23 8:30:00 AM ET
    $BON
    $SXTC
    $WSG
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Services-Misc. Amusement & Recreation

    Bon Natural Life Limited Announces Change to Board Composition

    XIAN, China, June 30, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appointment of Jeffrey Guzy, as a new independent Director to its Board of Directors and as Chair of the Audit Committee, both effective June 28, 2022. Effective June 27, 2022, Mr. Christopher Constable resigned as a director of the Company for personal reasons and stepped down as a member and chairman of the audit committee of the Board. The resignation of Mr. Constable did not result from any dispute or disagreement with the Company or the Board on any matter

    6/30/22 4:30:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Financials

    Live finance-specific insights

    View All

    Bon Natural Life Limited Announces FY2022 Earnings Release Date and Webcast

    Earnings to be released before market opens on Friday, February 10, 2023 XIAN, China, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2022 earnings release for the fiscal year ended September 30, 2021 before the market open on Friday, February 10, 2023. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be

    2/7/23 8:30:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bon Natural Life Limited Announces 2022 Half-Year Earnings Release Date and Webcast

    Earnings to be released before market opens on Monday, August 1, 2022XIAN, China, July 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its half-year earnings release for the reporting period ended March 31, 2022 before the market open on Monday, August 1, 2022. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be archived o

    7/28/22 4:30:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast

    Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2021 earnings release for the fiscal year ended September 30, 2021 before the market open on Monday, January 31, 2022. In observation of Chinese New Year, BON will host an investor conference call and webcast on February 3 beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, CMO Ms. Wenjuan Chen and COO Ms. Yingchun Xue. A replay

    1/28/22 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care